(NASDAQ: NRXP) Nrx Pharmaceuticals's forecast annual revenue growth rate of 647.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Nrx Pharmaceuticals's revenue in 2026 is $2,293,000.On average, 7 Wall Street analysts forecast NRXP's revenue for 2026 to be $3,175,797,210, with the lowest NRXP revenue forecast at $152,668,972, and the highest NRXP revenue forecast at $9,182,962,602. On average, 6 Wall Street analysts forecast NRXP's revenue for 2027 to be $11,150,196,868, with the lowest NRXP revenue forecast at $213,026,473, and the highest NRXP revenue forecast at $21,095,055,172.
In 2028, NRXP is forecast to generate $39,453,372,288 in revenue, with the lowest revenue forecast at $35,230,883,270 and the highest revenue forecast at $43,511,019,392.